Skip to search formSkip to main contentSkip to account menu

CT-011

Known as: CT 011 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pidilizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Agilent buys Her2 test firm
volume 30 number 8 august 2012 nature biotechnology inhibiting [only] apoptosis, it wouldn’t have worked so quickly.” Amplimmune… 
2012
2012
Amylin's $7 billion GLP-1 deal
volume 30 number 8 august 2012 nature biotechnology inhibiting [only] apoptosis, it wouldn’t have worked so quickly.” Amplimmune… 
2010
2010
Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma.
TPS305 Background: Follicular lymphoma (FL) is one of the most immune-responsive of all cancers. However, immunosuppressive… 
2010
2010
CT-011, Anti PD-1 Antibody, Enhances Ex-Vivo T Cell Responses To Autologous Dendritic/Myeloma Fusion Vaccine Developed For The Treatment Of Multiple Myeloma
2009
2009
In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.
Abstract 724 Background: Programmed death (PD)–1 is an inhibitory receptor that impairs the function of activated T-cells and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)